Company Overview of AmpliMed Corporation
AmpliMed Corporation, a clinical-stage cancer pharmaceutical company, develops small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone, which has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and Benzimidazole Series, small molecules with distinct structures which express tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.
4380 North Campbell Avenue
Tucson, AZ 85718
Founded in 1989
Key Executives for AmpliMed Corporation
Similar Private Companies By Industry
|Praetego, Inc.||United States|
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact AmpliMed Corporation, please visit www.amplimed.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.